#USA #New York #Pomerantz Law Firm #SEC Investigation #Capricor Therapeutics

Pomerantz LLP Investigates Capricor Therapeutics Investors' Concerns

Recently, Pomerantz LLP has initiated an investigation aimed at protecting the interests of investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR). This investigation focuses on alleged securities fraud and other unlawful business practices conducted by Capricor and certain individuals associated with the company.

The decimation of Capricor's stock price appears to stem from a series of developments that raised concerns among investors. On May 5, 2025, Capricor publicly announced the results of an FDA mid-cycle review for its Biologics License Application (BLA) for deramiocel, a promising treatment for Duchenne Muscular Dystrophy (DMD) cardiomyopathy. The press release made headlines by indicating that the FDA had confirmed plans to hold an advisory committee meeting concerning this application. However, just one day later, on May 6, 2025, Capricor's stock plummeted by 29.13%, closing at $7.30 per share. This drastic decline raised eyebrows and fueled suspicions of potential misconduct.

Adding to these concerns, an alarming report on June 20, 2025, from STAT revealed that the new head of the associated FDA unit had canceled the anticipated advisory meeting due to skepticism over the drug's efficacy and safety. This news further rattled investor confidence, leading Capricor's share price to drop an additional 30.82%, closing at $8.26 per share.

For investors, particularly those who acted on the assumption that Capricor's promising treatment would meet regulatory approval, these developments were devastating. Then, on July 11, 2025, Capricor received a Complete Response Letter (CRL) from the FDA regarding its BLA submission for deramiocel. The FDA stated it could not approve the BLA in its current form, citing insufficient evidence of effectiveness and the requirement for further clinical data.

On the heels of this critical letter, Capricor's share price again took a hit, falling 32.98% to close at $7.64 per share. This sequence of events raised significant alarm bells about the integrity of Capricor's management and their communications with investors.

In light of this situation, Pomerantz LLP invites any investors adversely affected by Capricor's stock price decline to reach out for assistance. With decades of experience in corporate, securities, and antitrust class litigation, Pomerantz is recognized as one of the foremost legal firms in this sector. They have recovered significant damages for victims of securities fraud and corporate misconduct, and they continue to uphold the rights of affected investors.

Investors can contact attorney Danielle Peyton at Pomerantz LLP for more information on how they might be impacted and what legal options are available to them. As of now, the firm has expressed intentions to pursue claims on behalf of those wronged by Capricor's actions and potentially recover damages resulting from the stock price collapse.

The firm emphasizes that past success is not indicative of future results, yet they remain committed to facilitating justice for their clients. The contact details for Danielle Peyton for further inquiries are available, and affected Capricor investors are encouraged to seek help and information about joining any possible class actions.

In an environment where transparency is paramount, the investigation undertaken by Pomerantz LLP serves as a crucial step in holding corporations accountable for their conduct. The situation remains fluid, and investors are advised to stay updated as the investigation continues to unfold.